On Monday, October 15, 2018, Judge Peter J. Messitte of the United States District Court, District of Maryland, convened a hearing on a motion by the NIH to dismiss a lawsuit (Case 8:18-cv-01130-PJM) by KEI regarding the decision by the… Continue Reading
On Monday morning, 10 September 2018, Knowledge Ecology International (KEI) delivered the following oral statement at the World Health Organization’s (WHO) Informal Discussion of the Roadmap Report on Access to Medicines and Vaccines 2019–2023. The morning session provided UN agencies,… Continue Reading
On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading
On August 20, 2018, KEI and T1International filed comments to the NIH regarding the prospective grant of an exclusive license to Inversago Pharma, a firm headquartered in Canada. According to the Federal Register notice 83 FR 38707, the NIH exclusive… Continue Reading
Below are the comments filed by Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) regarding a prospective grant of an exclusive license of NIH-owned patents to the California-based company Midissia Therapeutics. The prospective exclusive license is… Continue Reading
UPDATE: On Wednesday, 15 August 2018, WHO Director-General, Dr Tedros Adhanom Ghebreyesus provided a response to the open letter on the Roadmap on Access to Medicines and Vaccines 2019-2023. The Director-General’s response can be found here: WHO DG letter to… Continue Reading
The following are comments by the KEI on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, in response to notice in the Federal Register, 83 FR 22692. Overall, the Blueprint is very weak, and won’t do much… Continue Reading
Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading
July 10, 2018 Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager National Center for Advancing Translational Sciences National Institutes of Health Email sury.vepa@nih.gov Re: Prospective Grant of Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer to Apexx… Continue Reading
UPDATE: On July 13, 2018, KEI received a response to our comments on the prospective license to be given to ERYTHRYx Therapeutics. The brief response simply stated that NIH had already assessed the company to meet their technical and financial… Continue Reading